Is ARTHRALGIA a side effect of SORAFENIB (RAF KINASE INHIBITOR) ? ( FactMed.com )

About this FactMed analysis covering adverse side effect reports of SORAFENIB (RAF KINASE INHIBITOR) patients who developed ARTHRALGIA.

FactMed provides MD-approved analysis to help both patients, researchers, and physicians accurately assess the risk profile for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration and FactMed user submissions. Between January 2004 and October 2012, 111 individuals taking SORAFENIB (RAF KINASE INHIBITOR) reported ARTHRALGIA to the FDA. A total of 3329 SORAFENIB (RAF KINASE INHIBITOR) drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication.

FDA Research Report

Introduction This page is designed to help you determine the relationship, if any, between SORAFENIB (RAF KINASE INHIBITOR) and ARTHRALGIA. In doing so, we compare SORAFENIB (RAF KINASE INHIBITOR) with other drugs that cause ARTHRALGIA, to help you evaluate whether or not SORAFENIB (RAF KINASE INHIBITOR) causes ARTHRALGIA. Likewise, this page shows the most highly-reported side effects of SORAFENIB (RAF KINASE INHIBITOR), so you can see if ARTHRALGIA ranks among SORAFENIB (RAF KINASE INHIBITOR)'s most well-known side effects.

Summary Statistics
Reports of SORAFENIB (RAF KINASE INHIBITOR) causing ARTHRALGIA: 111
Reports of any side effect of SORAFENIB (RAF KINASE INHIBITOR) : 3329
Percentage of SORAFENIB (RAF KINASE INHIBITOR) patients where ARTHRALGIA is a reported side effect: 3.3343%

FDA reports of any drug causing ARTHRALGIA : 81289
Average percentage for all medicated patients where ARTHRALGIA is reported as a complication: 0.5095%

Physician opinion on SORAFENIB (RAF KINASE INHIBITOR) as adverse event culprit:

Overall opinion for all reports of this drug:

Most frequent diagnoses/indications for prescribing SORAFENIB (RAF KINASE INHIBITOR):

HEPATIC NEOPLASM MALIGNANT ( 770 patients )
RENAL CELL CARCINOMA ( 114 patients )
THYROID CANCER ( 65 patients )
METASTATIC RENAL CELL CARCINOMA ( 44 patients )
THYROID CANCER METASTATIC ( 35 patients )
BREAST CANCER ( 31 patients )
BREAST CANCER METASTATIC ( 27 patients )
GASTRIC CANCER ( 25 patients )
NON-SMALL CELL LUNG CANCER ( 25 patients )
COLORECTAL CANCER METASTATIC ( 22 patients )
RENAL CANCER ( 17 patients )
PRODUCT USED FOR UNKNOWN INDICATION ( 14 patients )
BILE DUCT CANCER ( 14 patients )
SALIVARY GLAND CANCER ( 7 patients )
HEPATIC CANCER METASTATIC ( 7 patients )
COLORECTAL CANCER ( 7 patients )
SMALL CELL LUNG CANCER STAGE UNSPECIFIED ( 6 patients )
RECTAL CANCER ( 5 patients )
PANCREATIC CARCINOMA ( 4 patients )
PROSTATE CANCER ( 4 patients )
INTRAOCULAR MELANOMA ( 4 patients )
HEPATIC NEOPLASM MALIGNANT RECURRENT ( 3 patients )
NEOPLASM ( 3 patients )
LIVER DISORDER ( 3 patients )
ANGIOSARCOMA ( 3 patients )
NON-SMALL CELL LUNG CANCER STAGE IV ( 3 patients )
METASTASES TO LUNG ( 3 patients )
HEPATIC NEOPLASM MALIGNANT NON-RESECTABLE ( 3 patients )
COLORECTAL CANCER STAGE IV ( 3 patients )
NEOPLASM MALIGNANT ( 3 patients )
GALLBLADDER CANCER METASTATIC ( 3 patients )
BILIARY CANCER METASTATIC ( 3 patients )
METASTASIS ( 3 patients )
COLON CANCER METASTATIC ( 2 patients )
HYPOPHARYNGEAL CANCER ( 2 patients )
DESMOID TUMOUR ( 2 patients )
NEUROENDOCRINE CARCINOMA ( 2 patients )
ACUTE MYELOID LEUKAEMIA (IN REMISSION) ( 2 patients )
LUNG NEOPLASM MALIGNANT ( 2 patients )
OESOPHAGEAL CARCINOMA ( 2 patients )
METASTATIC MALIGNANT MELANOMA ( 2 patients )
TONGUE NEOPLASM MALIGNANT STAGE UNSPECIFIED ( 2 patients )
METASTATIC SQUAMOUS CELL CARCINOMA ( 2 patients )
ANGINA PECTORIS ( 2 patients )
RENAL CELL CARCINOMA STAGE IV ( 2 patients )
OSTEOSARCOMA METASTATIC ( 2 patients )
BONE SARCOMA ( 2 patients )
METASTATIC OCULAR MELANOMA ( 2 patients )
METASTATIC SALIVARY GLAND CANCER ( 2 patients )
TONSIL CANCER ( 2 patients )
MYELODYSPLASTIC SYNDROME ( 1 patients )
PROSTATE CANCER METASTATIC ( 1 patients )
GALLBLADDER CANCER ( 1 patients )
NEUROENDOCRINE TUMOUR ( 1 patients )
MALIGNANT NEOPLASM OF RENAL PELVIS ( 1 patients )
GLIOMA ( 1 patients )
BLADDER CANCER ( 1 patients )
OVARIAN CANCER METASTATIC ( 1 patients )
CAROTID ARTERY DISEASE ( 1 patients )
HEPATOBLASTOMA ( 1 patients )
NASOPHARYNGEAL CANCER ( 1 patients )
ACUTE MYELOID LEUKAEMIA ( 1 patients )
LUNG ADENOCARCINOMA ( 1 patients )
RENAL CANCER METASTATIC ( 1 patients )
DIFFUSE LARGE B-CELL LYMPHOMA ( 1 patients )
NEUROENDOCRINE CARCINOMA OF THE SKIN ( 1 patients )
MALIGNANT HISTIOCYTOSIS ( 1 patients )
ANTICOAGULANT THERAPY ( 1 patients )
MALIGNANT SOFT TISSUE NEOPLASM ( 1 patients )
SARCOMA ( 1 patients )
GERM CELL CANCER ( 1 patients )
OESOPHAGEAL ADENOCARCINOMA ( 1 patients )
SQUAMOUS CELL CARCINOMA ( 1 patients )
HEAD AND NECK CANCER ( 1 patients )
OVARIAN EPITHELIAL CANCER ( 1 patients )
( 0 patients )

Drugs with high FDA adverse event association with ARTHRALGIA:

FOSAMAX (11612 patients)
HUMIRA (9494 patients)
ENBREL (8963 patients)
ASPIRIN (6039 patients)
VIOXX (5943 patients)
FORTEO (5794 patients)
METHOTREXATE (4903 patients)
LIPITOR (4427 patients)
ACCUTANE (4202 patients)
PREDNISONE (4117 patients)
ZOMETA (3931 patients)
REMICADE (3894 patients)
LEVAQUIN (3150 patients)
SYNTHROID (3116 patients)
NEXIUM (2885 patients)
FOLIC ACID (2883 patients)
CELEBREX (2683 patients)
LISINOPRIL (2533 patients)
SEROQUEL (2372 patients)
TYSABRI (2371 patients)
VITAMIN D (2359 patients)
OMEPRAZOLE (2273 patients)
AREDIA (2257 patients)
LASIX (2239 patients)
NEURONTIN (2217 patients)
PRILOSEC (2179 patients)
ATENOLOL (2146 patients)
AMBIEN (2068 patients)
COUMADIN (2060 patients)
CRESTOR (2048 patients)
LYRICA (1988 patients)
AVONEX (1975 patients)
HYDROCHLOROTHIAZIDE (1948 patients)
BONIVA (1910 patients)
ZOCOR (1905 patients)
ARIMIDEX (1903 patients)
CALCIUM (1896 patients)
XANAX (1885 patients)
SIMVASTATIN (1795 patients)
VICODIN (1782 patients)
ZOLOFT (1750 patients)
PREDNISONE TAB (1727 patients)
PROTONIX (1725 patients)
OXYCONTIN (1699 patients)
IBUPROFEN (1698 patients)
NORVASC (1686 patients)
ALENDRONATE SODIUM (1680 patients)
LEVOTHYROXINE SODIUM (1677 patients)
ACETAMINOPHEN (1588 patients)
PERCOCET (1560 patients)
PLAVIX (1546 patients)
PREVACID (1540 patients)
MAGNEVIST (1525 patients)
FUROSEMIDE (1519 patients)
ALBUTEROL (1514 patients)
CYMBALTA (1500 patients)
ACTONEL (1463 patients)
PREDNISOLONE (1447 patients)
RECLAST (1372 patients)
LEXAPRO (1344 patients)
TOPROL-XL (1314 patients)
PREMARIN (1284 patients)
GABAPENTIN (1227 patients)
ATIVAN (1216 patients)
DIOVAN (1213 patients)
LORAZEPAM (1191 patients)
SANDOSTATIN LAR (1163 patients)
POTASSIUM CHLORIDE (1156 patients)
FOSAMAX PLUS D (1150 patients)
MULTI-VITAMINS (1150 patients)
SINGULAIR (1139 patients)
DEXAMETHASONE (1098 patients)
OXYCODONE HCL (1085 patients)
ADVAIR DISKUS 100/50 (1083 patients)
LORTAB (1050 patients)
CHANTIX (1045 patients)
DIGOXIN (1042 patients)
PAXIL (1031 patients)
MULTI-VITAMIN (1030 patients)
FEMARA (1023 patients)
ALLOPURINOL (1020 patients)
METFORMIN HCL (1016 patients)
PROZAC (1010 patients)
CALCIUM CARBONATE (996 patients)
CLONAZEPAM (993 patients)
EFFEXOR (978 patients)
ZOFRAN (977 patients)
TRAMADOL HCL (942 patients)
FISH OIL (921 patients)
METOPROLOL TARTRATE (917 patients)
ALPRAZOLAM (915 patients)
ZETIA (913 patients)
CIPROFLOXACIN (907 patients)
AMOXICILLIN (902 patients)
FLEXERIL (902 patients)
LANTUS (901 patients)
VITAMIN E (901 patients)
WARFARIN SODIUM (896 patients)
ASCORBIC ACID (887 patients)
CELEXA (886 patients)
AVELOX (881 patients)
ZYRTEC (879 patients)
WELLBUTRIN (879 patients)
DURAGESIC-100 (876 patients)
DECADRON (856 patients)
KLONOPIN (843 patients)
ALLEGRA (829 patients)
VITAMIN B-12 (806 patients)
PLAQUENIL (803 patients)
VALIUM (801 patients)
AMLODIPINE (785 patients)
OMNISCAN (784 patients)
CIPRO (776 patients)
PEGASYS (761 patients)
SPIRIVA (759 patients)
ZANTAC (759 patients)
BENADRYL (754 patients)
NAPROXEN (740 patients)
TRAZODONE HCL (739 patients)
CALCIUM (UNSPECIFIED) (737 patients)
DILAUDID (733 patients)
MORPHINE (706 patients)
AMITRIPTYLINE HCL (706 patients)
TAMOXIFEN CITRATE (705 patients)
CIMZIA (698 patients)
DIAZEPAM (685 patients)
TYLENOL (683 patients)
NIASPAN (681 patients)
INSULIN (677 patients)
FLONASE (673 patients)
HYDROCODONE BITARTRATE (672 patients)
SOLIRIS (672 patients)
BYETTA (669 patients)
ZITHROMAX (660 patients)
COZAAR (659 patients)
REVLIMID (659 patients)
COREG (657 patients)
NITROGLYCERIN (656 patients)
TAXOTERE (654 patients)
TYLENOL (CAPLET) (651 patients)
COMPAZINE (647 patients)
AROMASIN (639 patients)
RANITIDINE (639 patients)
VITAMINS (UNSPECIFIED) (639 patients)
ELAVIL (632 patients)
ALEVE (626 patients)
GLUCOPHAGE (625 patients)
RIBAVIRIN (625 patients)
LOVENOX (623 patients)
EPOGEN (620 patients)
LANSOPRAZOLE (619 patients)
METOPROLOL (618 patients)
IRON (616 patients)
MOBIC (614 patients)
PRADAXA (614 patients)
HYDROCODONE (610 patients)
FENTANYL (606 patients)
CLONIDINE (605 patients)
CEPHALEXIN (604 patients)
REBIF (602 patients)
ACIPHEX (600 patients)
CHEMOTHERAPEUTICS NOS (600 patients)
ARANESP (596 patients)
LEVOXYL (596 patients)
ULTRAM (596 patients)
REGLAN (575 patients)
COLACE (575 patients)
ACTOS (572 patients)
EVISTA (570 patients)
MORPHINE SULFATE (562 patients)
BEXTRA (561 patients)
ALTACE (559 patients)
PEPCID (559 patients)
CLARITIN (549 patients)
TRICOR (548 patients)
LAMICTAL (547 patients)
EXJADE (547 patients)
THALIDOMIDE (542 patients)
ALEVE (CAPLET) (538 patients)
ACYCLOVIR (532 patients)
ARAVA (530 patients)
RITUXIMAB (526 patients)
LOPRESSOR (526 patients)
VYTORIN (523 patients)
MOTRIN (522 patients)
BACLOFEN (522 patients)
XELODA (522 patients)
GLUCOSAMINE (520 patients)
POTASSIUM (520 patients)
GLEEVEC (513 patients)
TOPAMAX (510 patients)
SOMA (501 patients)
PRAVACHOL (500 patients)
PROMETHAZINE (495 patients)
[THERAPY UNSPECIFIED] (494 patients)
CITALOPRAM HYDROBROMIDE (493 patients)
SPIRONOLACTONE (492 patients)
KEFLEX (492 patients)
METFORMIN (487 patients)
RADIATION THERAPY (485 patients)
GLIPIZIDE (485 patients)
MS CONTIN (483 patients)
VOLTAREN (480 patients)
PRAVASTATIN (471 patients)
MELOXICAM (468 patients)
TEMAZEPAM (467 patients)
CARBOPLATIN (465 patients)
FLOMAX (460 patients)
FERROUS SULFATE TAB (459 patients)
MIRENA (458 patients)

Most common side effects for patients taking SORAFENIB (RAF KINASE INHIBITOR):

DIARRHOEA (613 patients)
HEPATIC FAILURE (378 patients)
PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME (342 patients)
HEPATIC ENCEPHALOPATHY (320 patients)
FATIGUE (300 patients)
RASH (276 patients)
ASCITES (253 patients)
ABDOMINAL PAIN (237 patients)
DECREASED APPETITE (226 patients)
UPPER GASTROINTESTINAL HAEMORRHAGE (198 patients)
PYREXIA (191 patients)
ASPARTATE AMINOTRANSFERASE INCREASED (179 patients)
NAUSEA (165 patients)
HYPERTENSION (160 patients)
ASTHENIA (154 patients)
DEHYDRATION (140 patients)
HEPATIC FUNCTION ABNORMAL (133 patients)
DYSPNOEA (131 patients)
CONFUSIONAL STATE (131 patients)
HYPOKALAEMIA (125 patients)
ALOPECIA (124 patients)
VOMITING (118 patients)
CONSTIPATION (115 patients)
INTERSTITIAL LUNG DISEASE (114 patients)
LEFT VENTRICULAR DYSFUNCTION (113 patients)
DEATH (113 patients)
ENDOCARDITIS (112 patients)
ARTHRALGIA (111 patients)
STOMATITIS (111 patients)
ABDOMINAL PAIN UPPER (110 patients)
JAUNDICE (108 patients)
HEPATIC NEOPLASM MALIGNANT (106 patients)
GASTROINTESTINAL HAEMORRHAGE (106 patients)
RETINAL VASCULAR THROMBOSIS (103 patients)
LOWER GASTROINTESTINAL HAEMORRHAGE (103 patients)
LIVER CARCINOMA RUPTURED (101 patients)
OEDEMA PERIPHERAL (97 patients)
PLEURAL EFFUSION (97 patients)
STAPHYLOCOCCAL INFECTION (96 patients)
PNEUMONIA BACTERIAL (96 patients)
ENTEROBACTER INFECTION (96 patients)
MYOPATHY (95 patients)
DRY MOUTH (94 patients)
PAIN IN EXTREMITY (93 patients)
ANXIETY (90 patients)
MALAISE (89 patients)
PULMONARY EMBOLISM (85 patients)
ANAEMIA (84 patients)
PLATELET COUNT DECREASED (81 patients)
BACK PAIN (79 patients)
SEPSIS (78 patients)
PRURITUS (78 patients)
DUODENAL ULCER (77 patients)
MIGRAINE (76 patients)
MITRAL VALVE INCOMPETENCE (76 patients)
HYPOGLYCAEMIA (76 patients)
C-REACTIVE PROTEIN INCREASED (74 patients)
BLOOD PRESSURE INCREASED (73 patients)
VARICES OESOPHAGEAL (73 patients)
HEADACHE (72 patients)
RETINAL VEIN OCCLUSION (72 patients)
ABASIA (69 patients)
RENAL FAILURE ACUTE (69 patients)
WEIGHT DECREASED (67 patients)
DEEP VEIN THROMBOSIS (67 patients)
DIZZINESS (65 patients)
ERYTHEMA (65 patients)
GENERAL PHYSICAL HEALTH DETERIORATION (64 patients)
CONVULSION (63 patients)
ALANINE AMINOTRANSFERASE INCREASED (62 patients)
DYSPHONIA (62 patients)
CEREBRAL HAEMORRHAGE (60 patients)
APHAGIA (58 patients)
COLITIS (58 patients)
PNEUMONIA (57 patients)
GASTRIC ULCER (56 patients)
HYPONATRAEMIA (55 patients)
HAEMOGLOBIN DECREASED (53 patients)
RESPIRATORY FAILURE (52 patients)
LUNG DISORDER (52 patients)
CEREBRAL ISCHAEMIA (49 patients)
PARAESTHESIA (49 patients)
BLOOD BILIRUBIN INCREASED (48 patients)
GAIT DISTURBANCE (48 patients)
THYROID CANCER METASTATIC (44 patients)
DEPRESSED LEVEL OF CONSCIOUSNESS (43 patients)
PERICARDIAL EFFUSION (41 patients)
THROMBOCYTOPENIA (41 patients)
BLISTER (41 patients)
FEBRILE NEUTROPENIA (40 patients)
BLOOD LACTATE DEHYDROGENASE INCREASED (40 patients)
HALLUCINATION (40 patients)
CHILLS (40 patients)
AMMONIA INCREASED (39 patients)
SKIN ULCER (39 patients)
BLOOD ALKALINE PHOSPHATASE INCREASED (38 patients)
PAIN (38 patients)
HYPOALBUMINAEMIA (38 patients)
HYPOCALCAEMIA (37 patients)
FALL (37 patients)
POLLAKIURIA (37 patients)
BLOOD PRESSURE DECREASED (37 patients)
SKIN EXFOLIATION (37 patients)
INSOMNIA (36 patients)
CARDIAC ARREST (36 patients)
HYPOAESTHESIA (35 patients)
INFECTIOUS PERITONITIS (35 patients)
MYOCARDIAL INFARCTION (35 patients)
RETINAL VASCULAR DISORDER (34 patients)
RENAL FAILURE (34 patients)
LIPASE INCREASED (34 patients)
HYPERKALAEMIA (33 patients)
HYPERGLYCAEMIA (33 patients)
HAEMOPTYSIS (31 patients)
ATRIAL FIBRILLATION (30 patients)
GENERALISED OEDEMA (30 patients)
FAECAL INCONTINENCE (30 patients)
WHITE BLOOD CELL COUNT DECREASED (30 patients)
CELLULITIS (29 patients)
CHEST PAIN (29 patients)
SOMNOLENCE (29 patients)
HYPERBILIRUBINAEMIA (28 patients)
HYPOTENSION (28 patients)
MUSCLE SPASMS (28 patients)
ABDOMINAL DISTENSION (27 patients)
WHITE BLOOD CELL COUNT INCREASED (27 patients)
VISION BLURRED (27 patients)
HEPATIC PAIN (26 patients)
BLOOD ALBUMIN DECREASED (26 patients)
DYSURIA (25 patients)
RASH GENERALISED (25 patients)
BLOOD SODIUM DECREASED (25 patients)
BLOOD URIC ACID INCREASED (25 patients)
COMA (25 patients)
COUGH (25 patients)
PANCYTOPENIA (25 patients)
ACUTE ABDOMEN (24 patients)
EOSINOPHIL COUNT INCREASED (24 patients)
CEREBROVASCULAR ACCIDENT (24 patients)
METASTASES TO CENTRAL NERVOUS SYSTEM (23 patients)
CEREBRAL INFARCTION (23 patients)
HYPOMAGNESAEMIA (23 patients)
RETINAL VEIN THROMBOSIS (23 patients)
GAMMA-GLUTAMYLTRANSFERASE INCREASED (23 patients)
TUMOUR LYSIS SYNDROME (22 patients)
HYPOPHOSPHATAEMIA (22 patients)
INFECTION (22 patients)
ORAL PAIN (22 patients)
BLOOD CREATININE INCREASED (22 patients)
NEUTROPENIA (22 patients)
RENAL IMPAIRMENT (22 patients)
LETHARGY (22 patients)
SKIN TOXICITY (21 patients)
TONGUE BLISTERING (21 patients)
LIVER ABSCESS (21 patients)
HAEMATEMESIS (21 patients)
OESOPHAGEAL VARICES HAEMORRHAGE (20 patients)
MENTAL IMPAIRMENT (20 patients)
NERVOUSNESS (20 patients)
NEPHROTIC SYNDROME (20 patients)
HYPOPHAGIA (20 patients)
ADRENAL INSUFFICIENCY (19 patients)
DRY SKIN (19 patients)
BLOOD AMYLASE INCREASED (19 patients)
OEDEMA (19 patients)
INFECTIOUS PLEURAL EFFUSION (19 patients)
DYSPEPSIA (19 patients)
COMA HEPATIC (19 patients)
HEART RATE INCREASED (18 patients)
HYPERTENSIVE CRISIS (18 patients)
MYALGIA (18 patients)
ECZEMA (18 patients)
URINARY TRACT INFECTION (18 patients)
NEUROMYOPATHY (18 patients)
MEDICAL DEVICE COMPLICATION (18 patients)
DIVERTICULITIS (18 patients)
OSTEOMYELITIS (18 patients)
CEREBRAL ATROPHY (18 patients)
CEREBRAL VENTRICLE DILATATION (18 patients)
DIABETIC FOOT INFECTION (18 patients)
NECK PAIN (18 patients)
OLIGURIA (17 patients)
GASTROINTESTINAL DISORDER (17 patients)
HAEMATOCHEZIA (17 patients)
DISSEMINATED INTRAVASCULAR COAGULATION (17 patients)
HYPOTHYROIDISM (17 patients)
TRANSAMINASES INCREASED (17 patients)
OROPHARYNGEAL PAIN (17 patients)
CHRONIC MYELOID LEUKAEMIA (17 patients)
NEOPLASM PROGRESSION (17 patients)
METASTASES TO ADRENALS (16 patients)
LYMPHOCYTE COUNT DECREASED (16 patients)
INTERNATIONAL NORMALISED RATIO INCREASED (16 patients)
MULTI-ORGAN FAILURE (16 patients)
FEAR (16 patients)
PANCREATIC CARCINOMA (16 patients)
HYPERSOMNIA (16 patients)
EPILEPSY (16 patients)
SUBARACHNOID HAEMORRHAGE (16 patients)
METASTASES TO LUNG (16 patients)
TACHYCARDIA (16 patients)
MUSCULAR WEAKNESS (16 patients)
KLEBSIELLA SEPSIS (16 patients)
MYOCARDIAL ISCHAEMIA (16 patients)
DYSGEUSIA (16 patients)
LUNG INFECTION (16 patients)
FAECES DISCOLOURED (16 patients)
PAIN OF SKIN (16 patients)
SPINAL FRACTURE (16 patients)
PANIC REACTION (16 patients)

In addition to reviewing our up-to-date FDA research, users may interact with the FactMed community - currently one million members and growing! FactMed online research and discussions are read by patients, scientists, physicians, and other interested health care parties. Post follow up Questions to learn from our diverse readership. Likewise, patients who have experienced unwanted effects are encouraged to share their Concerns to help educate and inform our members.

Recent FactMed Activity for SORAFENIB (RAF KINASE INHIBITOR)

Issue	Description / Topic	Timestamp

My Patient Resources

Get your questions answered! Over one million patients, researchers, and health care providers have visited FactMed. If you have a question about ARTHRALGIA and SORAFENIB (RAF KINASE INHIBITOR), post it here. You may receive a response from a fellow patient - or a leading expert in the field.

Your Question:

Share your experience: Over one million patients, researchers, and health care providers have visited FactMed. If you have a noteworthy experience as a patient taking SORAFENIB (RAF KINASE INHIBITOR), post it here. Your story could help a fellow patient - or provide insight to a leading expert in the field.

Your Experience or Concern:

Telemedicine Expert Consults FactMed newest feature allows patients to consult - via realtime videoconferencing - experts in SORAFENIB (RAF KINASE INHIBITOR). This premium feature connects patients to experts, regardless of geography. FactMed experts charge reasonable rates that may be reimbursable by your insurance as a second-opinion.

We are currently accepting registration for SORAFENIB (RAF KINASE INHIBITOR) experts. If you are a healthcare provider experienced in prescribing SORAFENIB (RAF KINASE INHIBITOR), please register here.